Норвежская (корковая) чесотка у детей с когнитивными нарушениями: клинические случаи
Nikolay N. Murashkin,
Mariya A. Leonova,
Elen A. Grigoryan,
Alexandr I. Materikin,
Roman V. Epishev,
Dmitry V. Fedorov,
Roman A. Ivanov,
Ekaterina S. Pavlova,
Leonid A. Opryatin https://doi.org/10.15690/vsp.v24i4.2930
Abstract
Background. Diagnosis of Norwegian (crusted) scabies is complicated by clinical signs of chronic and acute skin diseases. Incorrect diagnosis and consequently irrational management lead to local immune system disorders and excessive reproduction of itch mites. Case description. Children with Prader–Willi syndrome and Down syndrome have shown signs of skin disease. The diagnosis of Norwegian scabies has been established according to dermatoscopy results and analysis of skin scraping from the lesion. External therapy included permethrin 5% lotion and showed positive dynamics of skin lesions over the next 7 days. Conclusion. Norwegian scabies is a difficult disease to diagnose. Particular attention should be given to patient's comorbidities and immune status. Dermatoscopy improves diagnostic accuracy. Topical permethrin therapy can be used as first-line therapy.
Supporting agencies: Not specified.
About the Authors
Nikolay N. Murashkin
National Medical Research Center of Children’s Health; Sechenov First Moscow State Medical University; Central State Medical Academy of Department of Presidential Affairs
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Nikolay N. Murashkin — receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Novartis, Abbvi, Pfizer, Amryt Pharma plc. Receiving fees for scientific counseling from companies Galderna, Pierre Fabre, Bayer, Leofarma, Pfizer, AbbVie, Zeldis Pharma. Other authors confirmed the absence of a reportable conflict of interests.
Mariya A. Leonova
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Nikolay N. Murashkin — receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Novartis, Abbvi, Pfizer, Amryt Pharma plc. Receiving fees for scientific counseling from companies Galderna, Pierre Fabre, Bayer, Leofarma, Pfizer, AbbVie, Zeldis Pharma. Other authors confirmed the absence of a reportable conflict of interests.
Elen A. Grigoryan
Russian Medical Academy of Continuing Professional Education
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Nikolay N. Murashkin — receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Novartis, Abbvi, Pfizer, Amryt Pharma plc. Receiving fees for scientific counseling from companies Galderna, Pierre Fabre, Bayer, Leofarma, Pfizer, AbbVie, Zeldis Pharma. Other authors confirmed the absence of a reportable conflict of interests.
Alexandr I. Materikin
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Nikolay N. Murashkin — receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Novartis, Abbvi, Pfizer, Amryt Pharma plc. Receiving fees for scientific counseling from companies Galderna, Pierre Fabre, Bayer, Leofarma, Pfizer, AbbVie, Zeldis Pharma. Other authors confirmed the absence of a reportable conflict of interests.
Roman V. Epishev
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Nikolay N. Murashkin — receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Novartis, Abbvi, Pfizer, Amryt Pharma plc. Receiving fees for scientific counseling from companies Galderna, Pierre Fabre, Bayer, Leofarma, Pfizer, AbbVie, Zeldis Pharma. Other authors confirmed the absence of a reportable conflict of interests.
Dmitry V. Fedorov
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Nikolay N. Murashkin — receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Novartis, Abbvi, Pfizer, Amryt Pharma plc. Receiving fees for scientific counseling from companies Galderna, Pierre Fabre, Bayer, Leofarma, Pfizer, AbbVie, Zeldis Pharma. Other authors confirmed the absence of a reportable conflict of interests.
Roman A. Ivanov
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Nikolay N. Murashkin — receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Novartis, Abbvi, Pfizer, Amryt Pharma plc. Receiving fees for scientific counseling from companies Galderna, Pierre Fabre, Bayer, Leofarma, Pfizer, AbbVie, Zeldis Pharma. Other authors confirmed the absence of a reportable conflict of interests.
Ekaterina S. Pavlova
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Nikolay N. Murashkin — receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Novartis, Abbvi, Pfizer, Amryt Pharma plc. Receiving fees for scientific counseling from companies Galderna, Pierre Fabre, Bayer, Leofarma, Pfizer, AbbVie, Zeldis Pharma. Other authors confirmed the absence of a reportable conflict of interests.
Leonid A. Opryatin
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Nikolay N. Murashkin — receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Novartis, Abbvi, Pfizer, Amryt Pharma plc. Receiving fees for scientific counseling from companies Galderna, Pierre Fabre, Bayer, Leofarma, Pfizer, AbbVie, Zeldis Pharma. Other authors confirmed the absence of a reportable conflict of interests.
References
1. Iyengar L, Chong AH, Steer AC. Scabies: a clinical update. Med J Aust. 2024;221(10):558–563. doi: https://doi.org/10.5694/mja2.52505
2. Cebeci D, Karasel S. Norwegian scabies in a child with Down syndrome. Sudan J Paediatr. 2021;21(2):215–218. doi: https://doi.org/10.24911/SJP.106-1599647837
3. Murashkin N.N., Ambarchian E.T., Materikin A.I., Epishev R.V. THE ROLE OF EPIDERMAL BARRIER IMPAIRMENTS IN ATOPIC DERMATITIS: MODERN CONCEPTS OF DISEASE PATHOGENESIS. Current Pediatrics. 2018;17(1):85–88. (In Russ.) https://doi.org/10.15690/vsp.v17i1.1859
4. Niode NJ, Adji A, Gazpers S, et al. Crusted Scabies, a Neglected Tropical Disease: Case Series and Literature Review. Infect Dis Rep. 2022;14(3):479–491. doi: https://doi.org/10.3390/idr14030051
5. Hugdahl E. Scabies — a public health problem. Tidsskr Nor Laegeforen. 2020;140(15). doi: https://doi.org/10.4045/tidsskr.20.0799
6. Garcia D, Farr M, Ross K. Misdiagnosis of Crusted Scabies: Skin Excoriations Resembling Brown Sugar Are Characteristic. Cutis. 2024;114(2):E24–E27. doi: https://doi.org/10.12788/cutis.1082
7. Sunderkötter C, Wohlrab J, Hamm H. Scabies: Epidemiology, Diagnosis, and Treatment. Dtsch Arztebl Int. 2021;118(41): 695–704. doi: https://doi.org/10.3238/arztebl.m2021.0296.
Review
For citations:
Murashkin N.N., Leonova M.A., Grigoryan E.A., Materikin A.I., Epishev R.V., Fedorov D.V., Ivanov R.A., Pavlova E.S., Opryatin L.A. Норвежская (корковая) чесотка у детей с когнитивными нарушениями: клинические случаи. Current Pediatrics. 2025;24(4):285-290. (In Russ.) https://doi.org/10.15690/vsp.v24i4.2930
Views:
3
Email this article 
